Canadian Cannabis Powerhouses: Stocks to Watch This Month
As of June 2025, the U.S. cannabis industry continues its rapid expansion. Projections estimate the market will reach approximately $45 billion in revenue this year. This growth is fueled by increasing consumer demand, introducing innovative products, and technological advancements in cultivation and production. Despite federal prohibition, 24 states have legalized adult-use cannabis, and 39 states have legalized medical cannabis. However, federal legalization efforts face challenges. In May 2025, the 1st U.S. Circuit Court of Appeals upheld the federal ban on marijuana, rejecting a legal challenge by several Massachusetts cannabis businesses. This decision underscores the ongoing tension between federal law and evolving state cannabis regulations. Additionally, while the Biden administration has proposed reclassifying marijuana to a less restricted category, the outcome remains uncertain, especially under a new administration.
Given this complex landscape, investors should approach cannabis stocks with caution. Implementing proper risk management strategies is essential. Utilizing technical analysis can help identify optimal entry and exit points, monitor price trends, and manage volatility. By combining these tools, investors can make informed decisions and navigate the cannabis sector’s dynamic environment effectively.
As global cannabis reform progresses, Canadian companies remain essential players in the market. In June 2025, three Canadian cannabis stocks stand out due to U.S. expansion efforts, product innovation, and improving financials. These companies are Tilray Brands, Organigram Holdings, and Aurora Cannabis. Each is taking a unique approach to build momentum in a challenging market. Investors looking for long-term exposure to the cannabis sector may want to watch these names closely.
[Read More] 3 Marijuana Stocks To Watch Next Month
3 Canadian Cannabis Stocks Poised for Growth in June 2025
- Tilray Brands Inc. (NASDAQ: TLRY)
- Organigram Holdings Inc. (NASDAQ: OGI)
- Aurora Cannabis Inc. (NASDAQ: ACB)
Tilray Brands Inc. (TLRY)
Tilray Brands is a leading global cannabis and consumer products company. It is headquartered in New York but was originally formed through a Canadian merger. While U.S. federal restrictions limit cannabis operations, Tilray has built a strong presence through alternative channels. The company distributes hemp-based THC beverages and has also acquired major craft beer companies. These moves expose Tilray to U.S. consumers while federal legalization is still pending.
Currently, Tilray does not operate cannabis dispensaries in the U.S. However, it sells its THC beverages in at least ten states, including markets like Florida, Alabama, and New Jersey. These beverages are sold in convenience stores, gas stations, and select retail outlets. Tilray’s multi-pronged approach allows it to build market share in both the cannabis and alcohol spaces. As regulations evolve, Tilray is positioned to scale quickly into full cannabis operations across the U.S.
Tilray posted $211 million in net revenue in its most recent quarterly report. This was a 9% increase from the previous year. Gross profit grew to $61 million, up 29%. However, the company also reported a net loss of $85 million. One-time expenses and non-cash charges drove this. Despite the loss, Tilray remains focused on long-term growth and profitability. It continues investing in key markets and expanding its branded product offerings. Currently, shares are trading under $1, making it a potential value play for long-term investors.
[Read More] These Top Marijuana Stocks Could Be The Low-Hanging Fruit In The Sector
Organigram Holdings Inc. (OGI)
Organigram Holdings is a top-tier licensed cannabis producer based in New Brunswick, Canada. The company has focused heavily on premium flower, extracts, and edibles. Recently, it expanded into the U.S. by acquiring a THC beverage manufacturer. This marked its first step into the American hemp-derived THC drink market. It plans to grow this segment through innovative flavors and national distribution agreements.
Although it does not yet operate dispensaries in the U.S., its beverage products are gaining attention. Organigram has won multiple awards for taste and product quality. The company is also known for its technological innovation. Its cultivation methods emphasize efficiency, quality, and consistency. These advantages give it an edge as global demand for premium cannabis products grows. Organigram’s goal is to lead in both Canadian and international markets, especially in emerging U.S. sectors.
Organigram recently reported record-breaking quarterly results. Net revenue reached $102.8 million, up 74% year-over-year. It was the first time the company exceeded $100 million in a single quarter. Net income also flipped positive, hitting $42.5 million. This was a sharp reversal from a $27.1 million loss the year prior. The growth came from strategic acquisitions and strong demand for its branded products. The company is also expanding in Europe and Australia, increasing global exposure. Its shares are currently priced just over $1, offering an affordable entry point for growth-focused investors.
[Read More] Top U.S. Marijuana Stocks to Add to Your Watchlist Right Now
Aurora Cannabis Inc. (ACB)
Aurora Cannabis is one of Canada’s most established cannabis producers. It focuses mainly on medical cannabis, which gives it access to global markets. Aurora has a strong presence in Europe and Australia. It does not currently operate U.S. dispensaries due to federal laws. However, its international reach allows it to grow without being solely dependent on North American recreational sales.
Aurora sells a variety of medical cannabis products, including dried flower, capsules, oils, and vapes. These products are prescribed by doctors and used to treat various health conditions. The company is also investing in pharmaceutical-grade production facilities. This ensures product quality meets strict standards in global medical markets. Aurora continues to streamline its operations to focus on high-margin segments like medical cannabis and international exports.
In its latest quarter, Aurora generated $81.1 million in net revenue. Notably, this marked a 29% increase over the previous year. Furthermore, medical cannabis accounted for 76% of total sales, totaling approximately $61.3 million. This represented a 41% year-over-year increase for the company’s medical segment. In addition, Aurora posted a record adjusted EBITDA of $10.1 million. Impressively, that figure reflected a 210% increase compared to the same period last year. Moreover, the company credits this growth to effective cost-cutting and improved product mix strategies. As a result, its stock is now trading near $5, which signals greater stability. In turn, this price action has helped restore investor confidence. Looking ahead, as global medical cannabis demand continues to expand, Aurora appears well-positioned to capitalize on future growth opportunities.
[Read More] Marijuana Market Set to Surge by 2030— Here Are This Week’s Top U.S. Stock Picks
Cannabis in Focus: 3 Canadian Stocks Set to Outperform
Canadian cannabis companies are adapting quickly to changes in global regulations. Though each of these three companies takes a different approach, they share a common goal—building sustainable and scalable cannabis operations. With a mix of international presence, U.S. market entry, and improving financials, Tilray, Organigram, and Aurora deserve a spot on your June 2025 watchlist. As always, proper risk management and technical analysis are key when evaluating entry points in this volatile sector.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
